168 related articles for article (PubMed ID: 22132977)
1. Regulation of deoxycytidine kinase expression and sensitivity to gemcitabine by micro-RNA 330 and promoter methylation in cancer cells.
Hodzic J; Giovannetti E; Diosdado B; Adema AD; Peters GJ
Nucleosides Nucleotides Nucleic Acids; 2011 Dec; 30(12):1214-22. PubMed ID: 22132977
[TBL] [Abstract][Full Text] [Related]
2. Methylation specific PCR to characterize methylation of the promoter of deoxycytidine kinase.
Peters GJ; Hodzic J; Ortega B; Giovannetti E; Adema AD; Broekhuizen R; Kaspers GJ; Hubeek I
Nucleosides Nucleotides Nucleic Acids; 2010 Jun; 29(4-6):408-13. PubMed ID: 20544528
[TBL] [Abstract][Full Text] [Related]
3. Detection of an alternatively spliced form of deoxycytidine kinase mRNA in the 2'-2'-difluorodeoxycytidine (gemcitabine)-resistant human ovarian cancer cell line AG6000.
Al-Madhoun AS; van der Wilt CL; Loves WJ; Padron JM; Eriksson S; Talianidis I; Peters GJ
Biochem Pharmacol; 2004 Aug; 68(4):601-9. PubMed ID: 15276067
[TBL] [Abstract][Full Text] [Related]
4. Physical and functional interactions between USF and Sp1 proteins regulate human deoxycytidine kinase promoter activity.
Ge Y; Jensen TL; Matherly LH; Taub JW
J Biol Chem; 2003 Dec; 278(50):49901-10. PubMed ID: 14514691
[TBL] [Abstract][Full Text] [Related]
5. Paclitaxel alters the expression and specific activity of deoxycytidine kinase and cytidine deaminase in non-small cell lung cancer cell lines.
Shord SS; Patel SR
J Exp Clin Cancer Res; 2009 Jun; 28(1):76. PubMed ID: 19500405
[TBL] [Abstract][Full Text] [Related]
6. Immunohistochemical and genetic evaluation of deoxycytidine kinase in pancreatic cancer: relationship to molecular mechanisms of gemcitabine resistance and survival.
Sebastiani V; Ricci F; Rubio-Viqueira B; Kulesza P; Yeo CJ; Hidalgo M; Klein A; Laheru D; Iacobuzio-Donahue CA
Clin Cancer Res; 2006 Apr; 12(8):2492-7. PubMed ID: 16638857
[TBL] [Abstract][Full Text] [Related]
7. Pretreatment deoxycytidine kinase levels predict in vivo gemcitabine sensitivity.
Kroep JR; Loves WJ; van der Wilt CL; Alvarez E; Talianidis I; Boven E; Braakhuis BJ; van Groeningen CJ; Pinedo HM; Peters GJ
Mol Cancer Ther; 2002 Apr; 1(6):371-6. PubMed ID: 12477049
[TBL] [Abstract][Full Text] [Related]
8. DCK is frequently inactivated in acquired gemcitabine-resistant human cancer cells.
Saiki Y; Yoshino Y; Fujimura H; Manabe T; Kudo Y; Shimada M; Mano N; Nakano T; Lee Y; Shimizu S; Oba S; Fujiwara S; Shimizu H; Chen N; Nezhad ZK; Jin G; Fukushige S; Sunamura M; Ishida M; Motoi F; Egawa S; Unno M; Horii A
Biochem Biophys Res Commun; 2012 Apr; 421(1):98-104. PubMed ID: 22490663
[TBL] [Abstract][Full Text] [Related]
9. Enhancement of gemcitabine sensitivity in pancreatic cancer by co-regulation of dCK and p8 expression.
Tang K; Zhang Z; Bai Z; Ma X; Guo W; Wang Y
Oncol Rep; 2011 Apr; 25(4):963-70. PubMed ID: 21225236
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of uptake and resistance to troxacitabine, a novel deoxycytidine nucleoside analogue, in human leukemic and solid tumor cell lines.
Gourdeau H; Clarke ML; Ouellet F; Mowles D; Selner M; Richard A; Lee N; Mackey JR; Young JD; Jolivet J; Lafrenière RG; Cass CE
Cancer Res; 2001 Oct; 61(19):7217-24. PubMed ID: 11585758
[TBL] [Abstract][Full Text] [Related]
11. [Expression of Gemcitabine-resistance-related gene and polymorphism of ribonucleotide reductase M1 gene promoter in Gemcitabine-resistant A549/Gem and NCI-H460/Gem cell lines].
Liu XQ; Wang WX; Lin L; Song ST
Zhonghua Zhong Liu Za Zhi; 2010 Jan; 32(1):17-21. PubMed ID: 20211060
[TBL] [Abstract][Full Text] [Related]
12. Exosomes confer chemoresistance to pancreatic cancer cells by promoting ROS detoxification and miR-155-mediated suppression of key gemcitabine-metabolising enzyme, DCK.
Patel GK; Khan MA; Bhardwaj A; Srivastava SK; Zubair H; Patton MC; Singh S; Khushman M; Singh AP
Br J Cancer; 2017 Feb; 116(5):609-619. PubMed ID: 28152544
[TBL] [Abstract][Full Text] [Related]
13. Acquisition of chemoresistance to gemcitabine is induced by a loss-of-function missense mutation of DCK.
Nakano T; Saiki Y; Kudo C; Hirayama A; Mizuguchi Y; Fujiwara S; Soga T; Sunamura M; Matsumura N; Motoi F; Unno M; Horii A
Biochem Biophys Res Commun; 2015 Sep; 464(4):1084-1089. PubMed ID: 26196746
[TBL] [Abstract][Full Text] [Related]
14. Stratification of nucleoside analog chemotherapy using 1-(2'-deoxy-2'-18F-fluoro-β-D-arabinofuranosyl)cytosine and 1-(2'-deoxy-2'-18F-fluoro-β-L-arabinofuranosyl)-5-methylcytosine PET.
Lee JT; Campbell DO; Satyamurthy N; Czernin J; Radu CG
J Nucl Med; 2012 Feb; 53(2):275-80. PubMed ID: 22302964
[TBL] [Abstract][Full Text] [Related]
15. dCK negatively regulates the NRF2/ARE axis and ROS production in pancreatic cancer.
Hu Q; Qin Y; Xiang J; Liu W; Xu W; Sun Q; Ji S; Liu J; Zhang Z; Ni Q; Xu J; Yu X; Zhang B
Cell Prolif; 2018 Aug; 51(4):e12456. PubMed ID: 29701272
[TBL] [Abstract][Full Text] [Related]
16. Downregulation of deoxycytidine kinase in cytarabine-resistant mantle cell lymphoma cells confers cross-resistance to nucleoside analogs gemcitabine, fludarabine and cladribine, but not to other classes of anti-lymphoma agents.
Klanova M; Lorkova L; Vit O; Maswabi B; Molinsky J; Pospisilova J; Vockova P; Mavis C; Lateckova L; Kulvait V; Vejmelkova D; Jaksa R; Hernandez F; Trneny M; Vokurka M; Petrak J; Klener P
Mol Cancer; 2014 Jun; 13():159. PubMed ID: 24972933
[TBL] [Abstract][Full Text] [Related]
17. Role of deoxycytidine kinase (dCK) activity in gemcitabine's radioenhancement in mice and human cell lines in vitro.
Grégoire V; Rosier JF; De Bast M; Bruniaux M; De Coster B; Octave-Prignot M; Scalliet P
Radiother Oncol; 2002 Jun; 63(3):329-38. PubMed ID: 12142097
[TBL] [Abstract][Full Text] [Related]
18. Synergistic cytotoxicity and pharmacogenetics of gemcitabine and pemetrexed combination in pancreatic cancer cell lines.
Giovannetti E; Mey V; Danesi R; Mosca I; Del Tacca M
Clin Cancer Res; 2004 May; 10(9):2936-43. PubMed ID: 15131028
[TBL] [Abstract][Full Text] [Related]
19. All-trans retinoic acid enhances gemcitabine cytotoxicity in human pancreatic cancer cell line AsPC-1 by up-regulating protein expression of deoxycytidine kinase.
Kuroda H; Tachikawa M; Uchida Y; Inoue K; Ohtsuka H; Ohtsuki S; Unno M; Terasaki T
Eur J Pharm Sci; 2017 May; 103():116-121. PubMed ID: 28215943
[TBL] [Abstract][Full Text] [Related]
20. Deoxycytidine kinase expression underpins response to gemcitabine in bladder cancer.
Kerr M; Scott HE; Groselj B; Stratford MR; Karaszi K; Sharma NL; Kiltie AE
Clin Cancer Res; 2014 Nov; 20(21):5435-45. PubMed ID: 25224279
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
